Visikol

Visikol is a contract research services company focused on accelerating the drug discovery and development process through providing clients with advanced tissue imaging and cell culture services. It counts all twenty of the top twenty pharmaceutical companies as clients and has been instrumental in dozens of drug discovery programs. The company provides services including 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, 2D and 3D cell culture assays, and ex vivo tissue slice assays. Visikol’s expertise lies in transforming tissues into actionable insights and bridging the gap between in vitro assays and in vivo results through best-in-class cell culture models.

In addition to its services, Visikol sells a suite of tissue clearing reagents and kits as well as the HUREL® Micro Liver portfolio of primary hepatocyte liver models. The company, founded in 2016 and headquartered in the United States, recently received a $1.63M grant investment, with the National Institutes of Health as the investor, on 26 April 2021.